Why is PCOS being renamed, and what does PMOS stand for?
On May 12, 2026, the Global Name Change Consortium published a landmark paper in The Lancet officially renaming PCOS (Polycystic Ovary Syndrome) to PMOS (Polyendocrine Metabolic Ovarian Syndrome). The paper was the culmination of 14 years of global collaboration involving over 22,000 survey responses from patients and clinicians across 56 patient and professional organizations worldwide.
The key finding that drove the rename: research confirmed there is no actual increase in abnormal ovarian cysts in the condition. The cysts the original name was built around are not a consistent or defining feature. They are stalled follicles, a consequence of disrupted follicle maturation, not the origin of the problem.
The new name carries specific clinical meaning. “Polyendocrine” reflects that this condition involves multiple hormonal systems: insulin, androgens, cortisol, and in many cases thyroid function. “Metabolic” places insulin resistance at the center of the clinical picture, where decades of research show it belongs. “Ovarian” acknowledges the reproductive consequences while no longer centering the ovaries as the source of the problem.
A 3-year global transition period is underway, with full implementation expected in the 2028 International Guideline update. Both names will appear in clinical settings during that window.
How does the metabolic framing change what PMOS means for fertility?
When PCOS was primarily understood as a structural or reproductive problem, the treatment pathway focused on managing its reproductive expressions: suppressing ovulation with hormonal contraception, inducing ovulation with Clomid or Letrozole, and using Metformin to address insulin resistance as a secondary concern.
The PMOS framing reverses that hierarchy. If the primary driver is metabolic, then the reproductive effects (irregular cycles, poor follicle development, low progesterone, and impaired egg quality) are downstream consequences of a metabolic environment that has not been adequately addressed.
This matters for fertility in several specific ways:
- Egg quality is directly affected. Elevated insulin drives excess androgen production in the ovary. Elevated intraovarian androgens impair mitochondrial function within the developing egg. Mitochondria produce the cellular energy (ATP) required for fertilization and early embryo division. A compromised mitochondrial environment in the egg explains why women with PMOS can have adequate follicle counts but still produce eggs with poor development potential.
- Ovulation quality matters, not just ovulation occurrence. Ovulation induction can trigger an egg release while the underlying metabolic environment remains disrupted. The egg that ovulates in an unaddressed PMOS environment is still maturing in a high-androgen, low-progesterone context. Inducing ovulation without addressing the metabolic root is like changing the tire on a car with engine problems.
- Progesterone production is affected. Granulosa cells impaired by excess androgens produce less progesterone after ovulation. Low luteal progesterone shortens the window for implantation and is a recognized contributor to early pregnancy loss and implantation failure.
- The IVF picture changes. Women with PMOS going into IVF often have high antral follicle counts and multiple retrieved eggs, but lower blastocyst conversion rates and higher embryo arrest rates than their egg numbers would predict. This pattern reflects egg quality impairment from the metabolic environment, and it is modifiable in the 90-day window before retrieval when the metabolic root is addressed.
If I have a PCOS diagnosis and normal labs, why do I still feel like something is wrong?
This is one of the most common experiences in women with PCOS, and the metabolic framing helps explain it.
The standard workup for PCOS evaluates fasting glucose, a testosterone level, and an ultrasound. Fasting glucose screens for established diabetes and prediabetes. It does not detect the earlier stage of insulin dysregulation where fasting insulin is already elevated and the hormonal disruption cascade is already active. A woman can have a fasting glucose of 88 mg/dL (well within normal range), a fasting insulin of 18 uIU/mL (functionally elevated), and a HOMA-IR of 3.4 (indicating significant insulin resistance) without a single lab value outside its reference range.
The feeling that something is wrong is physiologically accurate. It reflects the experience of living in a body that is sending dysregulated hormonal signals, producing suboptimal cycle function, and maturing eggs in a compromised environment, while being told on paper that everything looks fine.
The standard workup was not designed to catch subclinical metabolic dysfunction. It catches established disease. The gap between those two thresholds is where a significant number of women with PCOS have been living for years.
Specific tests that reveal what standard labs miss:
- Fasting insulin (target under 8 uIU/mL functionally, though standard ranges go higher)
- HOMA-IR (calculated from fasting glucose and fasting insulin; under 1.5 is optimal)
- Fasting glucose-to-insulin ratio (below 4.5 indicates insulin resistance regardless of individual values)
- Free testosterone alongside total testosterone (free testosterone reflects biologically active androgen exposure)
- SHBG (sex hormone-binding globulin; low SHBG means more free testosterone is circulating)
What does root-cause care for PMOS actually involve?
Root-cause care for PMOS addresses the metabolic environment directly, with the understanding that the reproductive effects will shift as the metabolic picture improves.
Blood sugar regulation. The single most impactful dietary change for insulin resistance is reducing the frequency and amplitude of postprandial insulin spikes. Eating protein before carbohydrates at each meal has been shown to reduce postprandial glucose by 25 to 37 percent and postprandial insulin by 16 to 20 percent. Pairing carbohydrates with protein and fat, eliminating standalone carbohydrate snacks, and maintaining consistent meal timing are practical entry points that do not require restrictive dieting.
Inositol supplementation. Myo-inositol (2,000 to 4,000 mg daily) functions as a second messenger in insulin signaling pathways and has demonstrated consistent improvements in fasting insulin, HOMA-IR, testosterone levels, and ovulatory frequency in multiple randomized controlled trials in PCOS populations. The evidence base for inositol in PCOS is stronger than for most other supplements commonly recommended in the fertility space.
Resistance training. Two to three sessions of resistance training per week activates GLUT4 translocation in muscle cells, an insulin-independent mechanism that increases glucose uptake without additional insulin signaling. This directly reduces the insulin load on the ovary and the androgen production that follows from it.
Nervous system regulation. Cortisol and insulin are closely linked. Chronic cortisol elevation from high-functioning stress, poor sleep, overtraining, or an overstimulated nervous system worsens insulin resistance and compounds androgen excess. In women with PMOS, nervous system regulation is not a secondary concern. It is part of the metabolic repair process.
Inflammation reduction. Chronic low-grade inflammation independently worsens insulin receptor sensitivity. Gut health, environmental toxin load, and inflammatory dietary patterns all contribute to the inflammatory baseline. Addressing them removes compounding stressors from the metabolic system.
How do I talk to my doctor about PMOS and make sure my care reflects the metabolic reality?
Most clinical encounters for PCOS are structured around symptom management rather than metabolic root-cause evaluation. Shifting that conversation is possible but requires coming in with specific language and specific data.
Request metabolic markers your workup likely did not include. Ask for fasting insulin alongside your fasting glucose at your next draw. If your provider does not routinely order it, explain that you are interested in evaluating insulin sensitivity as part of your fertility workup. Fasting insulin is a standard lab test; it is not a fringe request. Direct-to-consumer lab services (Ulta Lab Tests, Walk-In Lab) offer fasting insulin for under $30 if your provider declines.
Name the metabolic framing explicitly. Saying “I understand that PMOS is primarily a metabolic condition and I want to understand what we are doing to address the insulin and androgen component, not just the cycle symptoms” is a different conversation than asking “is my PCOS being managed correctly?” The first question is specific. It is harder to deflect with a generic answer.
Ask about Metformin if your HOMA-IR is above 2.0. Metformin is an insulin sensitizer with a strong evidence base for improving ovulatory frequency and IVF outcomes in insulin-resistant women. It is frequently not offered unless the patient raises the metabolic component directly, even when it is clinically indicated.
If you are not getting answers, consider a second opinion. A reproductive endocrinologist with a PCOS specialty or a functional medicine practitioner familiar with metabolic fertility care will approach the diagnosis with more granularity than a general OB-GYN managing cycle irregularity.
From Heather
The rename from PCOS to PMOS is something I have been waiting to see for a long time.
Not because the name itself matters that much, but because the name is a signal about where the medical conversation is directing its attention. For years, women with PCOS came to me after being told their diagnosis was being managed, when what was actually happening was that their symptoms were being suppressed and their metabolic root was completely untouched. Normal fasting glucose. Testosterone in range. Ultrasound unremarkable. And a body that was still not getting pregnant, still producing poor-quality eggs, still cycling irregularly, because the insulin picture had never been properly evaluated.
Inside The Egg Awakening, PMOS is one of the first things I assess for, and not just in women who carry the formal diagnosis. Many of the women I work with have never been told they have PCOS. Their cycles are regular enough, their ultrasounds are unremarkable, and their glucose is normal. But their fasting insulin tells a different story. And once we start addressing that metabolic environment, through blood sugar regulation, resistance training, inositol, nervous system work, the hormonal picture starts to shift. The cycle becomes more consistent. The luteal phase lengthens. The eggs develop in a better environment. That is the cascade the rename is trying to direct clinical care toward.
The rename does not fix the problem. But it does make it harder for a clinician to hand a woman a prescription and call her metabolic root addressed. That is progress.
